ALK and non-small cell lung carcinoma: In EGFR-mutated NSCLC, the prospective randomized COMPEL trial (NCT04765059) is examining the continuation of osimertinib versus placebo with chemotherapy after first-line osimertinib.89 In ALK+ NSCLC, retrospective analysis has suggested a significant benefit when a CNS-active ALK TKI is continued with chemotherapy after disease progression on next-generation ALK TKIs.90